Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Trial Profile

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs ADVM-022 (Primary) ; Corticosteroids
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms OPTIC
  • Sponsors Adverum Biotechnologies
  • Most Recent Events

    • 06 Jan 2019 According to an Adverum Biotechnologies media release, company will provide an update on enrollment from this trial in the first half of 2019. Interim data on the three cohorts are expected by the first quarter of 2020.
    • 19 Nov 2018 According to an Adverum Biotechnologies media release,first patient has been dosed.
    • 19 Nov 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top